International Pipeline and BD&L TA Oncology

Major accountabilities

• Accountable of delivery for all TA pipeline (pre-FDP transition) and BD&L activities through:
• Direct commercial input for select pipeline / BD&L assessments and strategy development as part of cross-functional pipeline, strategy, or BD&L assessment team(s).
• Leadership and guidance to TA cross-functional teams working on additional assessments, to pressure test and sense check recommendations, as well as problem solve or coach through challenges.
• Partnership with the Pipeline & BD&L hub to ensure that all TA activities are consistent with recommended International processes and governance, and that there is a continual dialogue on TA capacity, capabilities and challenges so that solutions can be developed.
• Partnership with NPP heads in Top3 International markets to create transparency on required TA pipeline & BD&L activities, as well as to pressure test, and synthesize Top3 market inputs prior to sharing with TAS teams or TA Head.
• Partnership with the TA Head to ensure activities are in line with TA and International priorities as outlined by the TAL or senior International leadership.
• Strong relationship with US TA to ensure that commonalities can be maximized, and differences can be elevated for appropriate discussion.

Elevate our ability to input into pipeline and BD&L over time

• Identify capability gaps across International teams and implement targeted tactics and upskilling activities to address them.
• Partner with Hub and other TA Pipeline and BD&L leads to enable transparency and sharing of learnings that can be leveraged across International markets and assets, to drive continuous improvement and consistent input to assets and BD&L projects.

Key Performance Indicators 

• Feedback from TA Head / TAL / International leaders on improvement of quality of input on pipeline and BD&L projects.
• Feedback from Top3 NPP heads on improvement in transparency and level of partnership.
• Delivery of pipeline and BD&L activities in accordance with Hub guidance and framewore

Requirements

• Minimum: Master’s Degree

  Desirable: MBA, Ph.D., M.D. or RPh 

• Existing expertise in Oncology
• 15+ years of commercial experience in a pharmaceutical, biotech, healthcare or consulting environment, including deep (5+ years) experience in:
• New Product Planning / pipeline strategy (including early programs, IDPA / TDP).
• Leading commercial input to BD&L business case assessments for pipeline or marketed assets.
• Indication or disease area strategy development (i.e. has held strategic accountabilities beyond the individual asset level).
• Strong technical understanding of the asset development process, including direct experience influencing GPTs and GPHs to shape a CDP for TDP and FDP (Lead will not be a member of Early GPTs in accordance with the Enterprise operating model, needs to have a strong familiarity with how they operate to provide the most valuable and relevant International input to TAS leads).
• Significant (3+ years) experience working either with or within International Top3 market(s) on pipeline or BD&L assessments.
• Strong cross functional leadership, effectively work in matrix balancing cross-functional perspectives and alignment with business priorities across multiple stakeholders.
• Able to establish credibility and influence across a range of diverse stakeholders in a matrix organization to drive change.
• Entrepreneurial and growth mindset.
• Able to learn quickly and adapt in a complex environment, apply learning and remain resilient; know how to navigate the matrix to drive change.
• Able to translate strategy into flawless execution and drive consistency; able to link interdependencies in the portfolio.
• Essential: Fluent written and spoken English

Preferred:

• Experience across multiple functions including Commercial, Insights & Analytics, Market Access.